


**PRODUCT: PIK-75**

<b>ALTERNATE NAMES:</b>	PIK75; PIK 75; PIK-75 Hydrochloride; PIK75 Hydrochloride; PIK 75 Hydrochloride; (E)-N'-((6-bromoH-imidazo[1,2-a]pyridin-3-yl)methylene)-N,2-dimethyl-5-nitrobenzenesulfonohydrazide hydrochloride; PIK-75 Hydrochloride; PIK75 Hydrochloride; PIK 75 Hydrochloride
<b>CATALOG#:</b>	B1668-5, -25
<b>AMOUNT:</b>	5 mg, 25 mg
<b>STRUCTURE:</b>	
<b>MOLECULAR FORMULA:</b>	C <sub>16</sub> H <sub>15</sub> BrClN <sub>5</sub> O <sub>4</sub> S
<b>MOLECULAR WEIGHT:</b>	488.74
<b>CAS NUMBER:</b>	372196-77-5
<b>APPEARANCE:</b>	Solid powder
<b>SOLUBILITY:</b>	DMSO
<b>PURITY:</b>	>98%
<b>STORAGE:</b>	Dry, dark and at 4°C for short term (days to weeks) or at -20°C for long term. Protect from air and light.
<b>DESCRIPTION:</b>	PIK-75 is a p110α inhibitor with IC50 of 5.8 nM (200-fold more potently than p110β), isoform-specific mutants at Ser773, and also potently inhibits DNA-PK with IC50 of 2 nM.
<b>HANDLING:</b>	Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
<b>REFERENCES:</b>	<ol style="list-style-type: none"> <li>Zheng Z et al. Isoform-selective inhibition of phosphoinositide 3-kinase: identification of a new region of nonconserved amino acids critical for p110α inhibition. <i>Mol Pharmacol.</i> 2011 Oct;80(4):657-64.</li> <li>Thomas D et al. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. <i>Blood.</i> 2013 Aug 1;122(5):738-48.</li> </ol>

**RELATED PRODUCTS:**

- APY-0201 (Cat. No. 9564-5,25)
- AS-604850 (Cat. No. 2339-1, 5)
- BAG956 (Cat.No. 2456-5, 25)
- BAY 80-6946 (Cat. No. B1267-5,25)
- BEZ235 (NVP-BEZ235) (Cat. No. 1626-5, 25)
- CAL-101 (Cat. No. 2613-5, 25)
- GDC-0941 bismesylate (Cat. No. 1623-1, 5)
- Deforolimus (Cat. No. 1587-5, 25)
- DiscoveryPak™ PI 3-Kinase Inhibitor Panel (Cat. No. K856-5)
- GDC-0941 (Cat. No. 1623-1,5)
- GSK-263771 (Cat. No. 2793-5, 25)
- IC87114 (Cat. No. 1661-1)
- IPI-145 (Cat. No. 2445-5, 25)
- LY 294002 (Cat. No. 1667-5, 25)
- NVP-BKM120 (Cat. No. 2619-5, 25)
- mTOR Inhibitor, Ku-0063794 (Cat. No. 1779-1,5)
- OSU-03012, hydrochloride (Cat. No. 2295-5, 25)
- PI-103 (Cat. No. 1728-1,5)
- PIK-294 (Cat. No. 2614-5, 25)
- PI3-Ky Inhibitor, AS-605240 (Cat. No. 1780-1,5)
- PathwayReady™ PI3-K/Akt/mTOR Signaling Inhibitor panel (Cat. No. K857-11)
- PP242 (Cat. No. 1658-1)
- PX-866 (Cat. No. 1965-1, 5)
- Rapamycin (Cat. No. 1568-5, 50)
- SAR260301 (Cat. No. B1263-5,25)
- Temsirolimus (Cat. No. 1600-5, 25)
- TGX-115 (Cat. No. 1660-1)
- TGX-221 (Cat. No. 1781-1,5)
- Wortmannin (Cat. No. 1670-1)
- YM201636 (Cat. No. 2045-1, 5)
- XL147 (Cat. No. 9401-5, 25)
- TGX-115 (Cat. No. 1660-1)
- TGX-221 (Cat. No. 1781-1, 5)
- Wortmannin (Cat. No. 1670-1)

**USAGE:** *FOR RESEARCH USE ONLY! Not to be used in humans*